Mi-BMSCs alleviate inflammation and fibrosis in CCl4-and TAA-induced liver cirrhosis by inhibiting TGF-β/Smad signaling

doi:10.1016/j.mtbio.2024.100958

科研成果详情

题名	Mi-BMSCs alleviate inflammation and fibrosis in CCl4-and TAA-induced liver cirrhosis by inhibiting TGF-β/Smad signaling
作者	Shi, Qing 1; Xia, Yuhan 1; Wu, Minmin1; Pan, Yating1; Wu, Shiyi1; Lin, Jiawei1; Kong, Yifan1; Yu, Zhijie2; Zan, Xingjie 3; Liu, Pixu1; Xia, Jinglin1,4,5
发表日期	2024-04
发表期刊	Materials today. Bio 影响因子和分区
语种	英语
原始文献类型	Journal Article ; Article ; Journal article (JA)
关键词	Bone marrow mesenchymal stem cells Fibrosis Liver cirrhosis Porous microspheres TGF-β/Smad Biocompatibility Bone Cell culture Chlorine compounds Disease control Flowcharting Stem cells Bone marrow Bone marrow mesenchymal Bone marrow mesenchymal stem cell Fibrose Marrow mesenchymal stem cells Mesenchymal stem cell TGF-β TGF-β/smad
其他关键词	MESENCHYMAL STEM-CELLS ; MECHANISMS ; MICROFLUIDICS ; CULTURE ; TISSUE ; BONE
摘要	Cirrhosis is an aggressive disease, and over 80 % of liver cancer patients are complicated by cirrhosis, which lacks effective therapies. Transplantation of mesenchymal stem cells (MSCs) is a promising option for treating liver cirrhosis. However, this therapeutic approach is often challenged by the low homing ability and short survival time of transplanted MSCs in vivo. Therefore, a novel and efficient cell delivery system for MSCs is urgently required. This new system can effectively extend the persistence and duration of MSCs in vivo. In this study, we present novel porous microspheres with microfluidic electrospray technology for the encapsulation of bone marrow-derived MSCs (BMSCs) in the treatment of liver cirrhosis. Porous microspheres loaded with BMSCs (Mi-BMSCs) exhibit good biocompatibility and demonstrate better anti-inflammatory properties than BMSCs alone. Mi-BMSCs significantly increase the duration of BMSCs and exert potent anti-inflammatory and anti-fibrosis effects against CCl4 and TAA-induced liver cirrhosis by targeting the TGF-β/Smad signaling pathway to ameliorate cirrhosis, which highlight the potential of Mi-BMSCs as a promising therapeutic approach for early liver cirrhosis
资助项目	Discipline Cluster of Oncology, Wenzhou Medical University[z2-2023015];Major scientific and technological innovation project of Wenzhou Science and Technology Bureau[ZY2021009];Natural Science Foundation of Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province[G2023003];Shanghai Clinical Research Center for Interventional Medicine[19MC1910300];National Natural Science Foundation of China[81972233];Zhejiang Provincial Natural Science Foundation of China[LY24H160028];
出版者	Elsevier B.V.
ISSN	2590-0064
EISSN	2590-0064
卷号	25
DOI	10.1016/j.mtbio.2024.100958
页数	16
WOS类目	Engineering, Biomedical ; Materials Science, Biomaterials
WOS研究方向	Engineering ; Materials Science
WOS记录号	WOS:001178863900001
收录类别	PUBMED ; SCIE ; SCOPUS ; EI
EI入藏号	20240615509194
EI主题词	Microspheres
EI分类号	461.2 Biological Materials and Tissue Engineering ; 461.9.1 Immunology ; 723.1 Computer Programming
URL	查看原文
PubMed ID	38327975
SCOPUSEID	2-s2.0-85184059360
通讯作者地址	[Zan, Xingjie]Wenzhou Institute,Wenzhou Key Laboratory of Perioperative Medicine,University of Chinese Academy of Sciences,Wenzhou,325001,China ; [Liu, Pixu]Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province,The First Affiliated Hospital of Wenzhou Medical University,Zhejiang,Wenzhou,325000,China ; [Xia, Jinglin]Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province,The First Affiliated Hospital of Wenzhou Medical University,Zhejiang,Wenzhou,325000,China
Scopus学科分类	Biotechnology;Bioengineering;Biomaterials;Biomedical Engineering;Molecular Biology;Cell Biology
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/207582
专题	附属第一医院
通讯作者	Zan, Xingjie; Liu, Pixu; Xia, Jinglin
作者单位	1.Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province,The First Affiliated Hospital of Wenzhou Medical University,Zhejiang,Wenzhou,325000,China; 2.Wenzhou Key Laboratory of Hematology,The First Affiliated Hospital of Wenzhou Medical University,Zhejiang,Wenzhou,325000,China; 3.Wenzhou Institute,Wenzhou Key Laboratory of Perioperative Medicine,University of Chinese Academy of Sciences,Wenzhou,325001,China; 4.Liver Cancer Institute,Zhongshan Hospital of Fudan University,Shanghai,200032,China; 5.National Clinical Research Center for Interventional Medicine,Shanghai,200032,China
第一作者单位	附属第一医院
通讯作者单位	附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Shi, Qing,Xia, Yuhan,Wu, Minmin,et al. Mi-BMSCs alleviate inflammation and fibrosis in CCl4-and TAA-induced liver cirrhosis by inhibiting TGF-β/Smad signaling[J]. Materials today. Bio,2024,25.
APA	Shi, Qing., Xia, Yuhan., Wu, Minmin., Pan, Yating., Wu, Shiyi., ... & Xia, Jinglin. (2024). Mi-BMSCs alleviate inflammation and fibrosis in CCl4-and TAA-induced liver cirrhosis by inhibiting TGF-β/Smad signaling. Materials today. Bio, 25.
MLA	Shi, Qing,et al."Mi-BMSCs alleviate inflammation and fibrosis in CCl4-and TAA-induced liver cirrhosis by inhibiting TGF-β/Smad signaling".Materials today. Bio 25(2024).